Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways
Current antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination admi...
| Published in: | Emerging Microbes and Infections |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2026-12-01
|
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205 |
| _version_ | 1875639674740932608 |
|---|---|
| author | Lili Tian Hongbo Qin Sha Li Mengjie Zhang Lu Zhuang Bixia Hong Ke Liu Maochen Li Siyue Li Yaxin Wang Lihua Song Yang Liu Yun Wang Huiyu Liu Yigang Tong Huahao Fan |
| author_facet | Lili Tian Hongbo Qin Sha Li Mengjie Zhang Lu Zhuang Bixia Hong Ke Liu Maochen Li Siyue Li Yaxin Wang Lihua Song Yang Liu Yun Wang Huiyu Liu Yigang Tong Huahao Fan |
| author_sort | Lili Tian |
| collection | DOAJ |
| container_title | Emerging Microbes and Infections |
| description | Current antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination administration of lactoferrin with brincidofovir or tecovirimat demonstrated additive efficacy, suggesting a potential clinical strategy to reduce individual drug toxicity. Mechanistically, lactoferrin blocks viral entry by competitively binding to heparan sulphate proteoglycans (HSPGs). It also suppresses viral replication by regulating host antiviral pathways, including down-regulating cytokines and upregulating TGF-β-dependent antiviral signalling pathways. We identify TGFBI as a virus-responsive target regulated by lactoferrin. Lactoferrin treatment restores TGFBI expression and activates downstream MAPK/ERK and JAK2/STAT3 signalling cascades, leading to enhanced interferon production and interferon-stimulated gene (ISG) expression. In a murine vaccinia virus (VACV) infection model, lactoferrin treatment reduced lung viral loads and histological damage. These results underscore lactoferrin's distinctive dual antiviral mechanism and highlight its translational potential as a safe and cost-effective prophylactic or therapeutic agent. It is particularly beneficial for immunocompromised populations in resource-limited settings during orthopoxvirus outbreaks. |
| format | Article |
| id | doaj-art-cb86f00d7f3b42e392ff4e1e2f2feb3a |
| institution | Directory of Open Access Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2026-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| spelling | doaj-art-cb86f00d7f3b42e392ff4e1e2f2feb3a2026-05-12T07:36:31ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512026-12-0115110.1080/22221751.2026.2631205Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathwaysLili Tian0Hongbo Qin1Sha Li2Mengjie Zhang3Lu Zhuang4Bixia Hong5Ke Liu6Maochen Li7Siyue Li8Yaxin Wang9Lihua Song10Yang Liu11Yun Wang12Huiyu Liu13Yigang Tong14Huahao Fan15College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, People’s Republic of ChinaDepartment of Pediatric Medicine, the Seventh Medical Center of Chinese PLA General Hospital, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaSchool of Life Sciences, Tianjin University, Tianjin, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaInstitute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen, People’s Republic of ChinaWuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCollege of Life Science and Technology, Beijing University of Chemical Technology, Beijing, People’s Republic of ChinaCurrent antiviral therapies for orthopoxviruses face critical challenges, including limited efficacy and significant toxicity, which impede outbreak containment and clinical management. Here, we identify lactoferrin as a potent antiviral agent against multiple orthopoxvirus strains. Combination administration of lactoferrin with brincidofovir or tecovirimat demonstrated additive efficacy, suggesting a potential clinical strategy to reduce individual drug toxicity. Mechanistically, lactoferrin blocks viral entry by competitively binding to heparan sulphate proteoglycans (HSPGs). It also suppresses viral replication by regulating host antiviral pathways, including down-regulating cytokines and upregulating TGF-β-dependent antiviral signalling pathways. We identify TGFBI as a virus-responsive target regulated by lactoferrin. Lactoferrin treatment restores TGFBI expression and activates downstream MAPK/ERK and JAK2/STAT3 signalling cascades, leading to enhanced interferon production and interferon-stimulated gene (ISG) expression. In a murine vaccinia virus (VACV) infection model, lactoferrin treatment reduced lung viral loads and histological damage. These results underscore lactoferrin's distinctive dual antiviral mechanism and highlight its translational potential as a safe and cost-effective prophylactic or therapeutic agent. It is particularly beneficial for immunocompromised populations in resource-limited settings during orthopoxvirus outbreaks.https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205Monkeypoxorthopoxvirusbreast milklactoferrinantiviral therapyheparan sulphate |
| spellingShingle | Lili Tian Hongbo Qin Sha Li Mengjie Zhang Lu Zhuang Bixia Hong Ke Liu Maochen Li Siyue Li Yaxin Wang Lihua Song Yang Liu Yun Wang Huiyu Liu Yigang Tong Huahao Fan Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways Monkeypox orthopoxvirus breast milk lactoferrin antiviral therapy heparan sulphate |
| title | Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| title_full | Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| title_fullStr | Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| title_full_unstemmed | Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| title_short | Lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| title_sort | lactoferrin blocks orthopoxvirus entry via heparan sulphate and regulates host antiviral pathways |
| topic | Monkeypox orthopoxvirus breast milk lactoferrin antiviral therapy heparan sulphate |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2026.2631205 |
| work_keys_str_mv | AT lilitian lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT hongboqin lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT shali lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT mengjiezhang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT luzhuang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT bixiahong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT keliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT maochenli lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT siyueli lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT yaxinwang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT lihuasong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT yangliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT yunwang lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT huiyuliu lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT yigangtong lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways AT huahaofan lactoferrinblocksorthopoxvirusentryviaheparansulphateandregulateshostantiviralpathways |
